Marker Therapeutics MRKR
NASDAQ MRKR
$1.07 -0.06 (-5.31%)
At close: Oct 22, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014)

Updated

Marker Therapeutics (MRKR) posted Convertible Debt of $52,942 for Q4 2014.

Analysis

Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014) Analysis & Trends

  • The Q4 2014 figure stands as the highest quarterly Convertible Debt since Q3 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Marker Therapeutics 20.86 Mn -39.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 52,942.00
Sep 30, 2011 568,127.00
Jun 30, 2011 504,469.00
API Access

Marker Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=MRKR&period=max&api_key=YOUR_API_KEY